EUAs were issued by the FDA using the following criteria:
1. SARS-CoV-2, the virus that causes COVID-19, can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus
2. Based on the totality of scientific evidence and other information available to FDA, it is reasonable to believe that the products may be effective in preventing wearer exposure to pathogenic biological airborne particulates during filtering facepiece respirator (FFR) shortages, and that the known and potential benefits of the authorized respirators, when used for such use, outweigh the known and potential risks of such products
3. There is no adequate, approved, and available alternative to the emergency use of these respirator models for preventing healthcare personnel or providers (HCP) exposure to such particulates during FFR shortages to prevent disease spread during the COVID-19 emergency.
EUAs are effective until the declaration that circumstances exist justifying the authorization of the emergency use of personal respiratory protective devices during the COVID-19 outbreak is terminated or the EUA is revoked.
On June 30, 2021, the FDA announced the revocation of the following EUAs:
- Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators (effective July 6, 2021)
- Non-NIOSH-Approved Disposable Filtering Facepiece Respirators Manufactured in China (effective July 6, 2021)
- Decontamination and Bioburden Reduction System EUAs for Personal Protective Equipment (effective June 30, 2021)
As of the effective date of the revocations, these devices are no longer authorized for use in healthcare settings, as access to FDA-authorized and NIOSH-approved N95s increases nationwide.
Is your company manufacturing, exporting or distributing other medical devices?
Under the Medical Device User Fee Amendments (MDUFA), medical device companies pay fees to the FDA when they register their establishments and list their devices.
$5,672.00 | Establishment Registration Fee, annual (FY 2022)
Keep in mind that this fee will increase on October 1, 2022.
Premarket Notification 510(k) – Standard Fee: $12,745.00. Small Business Fee: $3,186.00 (Fiscal Year 2022). Exempt medical devices do not incur this fee.
FDA is using Dun & Bradstreet Inc to conduct verification of medical device facility information provided to the agency by registered and listed medical device manufacturers.
- Company Registration
- Product Listing
- U.S. Agent Service